Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Blackhall

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
ESMO Open|January 30, 2021
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS studyF Gomes, P Lorigan, S Woolley, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2008
Radiotherapy for small-cell lung cancer-Where are we heading?N A Bayman, H Sheikh, B Kularatne, et al.
ESMO Open|April 30, 2022
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancerN Tinsley, C Zhou, S Nahm, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2013
Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the ChristieM Evans, Y Summers, P Taylor, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2015
Outcomes of octogenarian (≥ 80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie HospitalM Howell, J Chiramel, N Flaum, et al.
Clinical and Translational Radiation Oncology|March 22, 2021
Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancerK Haslett, P Koh, A Hudson, et al.
British Journal of Cancer|July 2, 2014
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testingS Patton, N Normanno, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Optimisation of circulating biomarkers of cell death for routine clinical useA Greystoke, J Cummings, T Ward, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
ESMO Open|January 30, 2021
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS studyF Gomes, P Lorigan, S Woolley, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2008
Radiotherapy for small-cell lung cancer-Where are we heading?N A Bayman, H Sheikh, B Kularatne, et al.
ESMO Open|April 30, 2022
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancerN Tinsley, C Zhou, S Nahm, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2013
Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the ChristieM Evans, Y Summers, P Taylor, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2015
Outcomes of octogenarian (≥ 80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie HospitalM Howell, J Chiramel, N Flaum, et al.
Clinical and Translational Radiation Oncology|March 22, 2021
Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancerK Haslett, P Koh, A Hudson, et al.
British Journal of Cancer|July 2, 2014
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testingS Patton, N Normanno, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Optimisation of circulating biomarkers of cell death for routine clinical useA Greystoke, J Cummings, T Ward, et al.
Pageof 4